It is interesting to notice that studies have observed that the overall incidence of HER2 positivity in pT1mi tumors ranges from 37% to 57.4% [25,26], much higher than in larger size invasive carcinoma (10–20%) and pure DCIS (13–20%) [27,28]. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.